Reference : 2- and 4-[18F]fluorotropapride, two specific D2 receptor ligands for positron emissio...
Scientific journals : Article
Physical, chemical, mathematical & earth Sciences : Chemistry
http://hdl.handle.net/2268/5370
2- and 4-[18F]fluorotropapride, two specific D2 receptor ligands for positron emission tomography: N.C.A. syntheses and animal studies.
English
Damhaut, Philippe [> > > >]
Cantineau, Robert [> > > >]
Lemaire, Christian mailto [Université de Liège - ULg > > Centre de recherches du cyclotron >]
Plenevaux, Alain mailto [Université de Liège - ULg > > Centre de recherches du cyclotron >]
Christiaens, Léon [> > > >]
Guillaume, Marcel [> > > >]
1992
International Journal of Radiation Applications and Instrumentation. Part A : Applied Radiation and Isotopes
Pergamon Press
43
10
1265-74
Yes (verified by ORBi)
International
0883-2889
Oxford
United Kingdom
[en] Animals ; Brain/radionuclide imaging ; Fluorine Radioisotopes ; Isotope Labeling/methods ; Nortropanes ; Rats ; Receptors, Dopamine D2 ; Tomography, Emission-Computed
[en] Tropapride, (exo)-2,3-dimethoxy-N-[8-(phenylmethyl)-8- azabicyclo[3.2.1]oct-3-yl]benzamide hydrochloride, has been labeled with fluorine-18 at the 2- and 4-positions of its benzylic group. Two synthetic pathways were investigated: the first one required the alkylation of the norbenzyl precursor with 2- or 4-[18F]fluorobenzyl bromide (radiochemical yield of 5% EOB, 180 min); the second method consisted of a reductive amination of norbenzyl tropapride with 2- or 4-[18F]fluorobenzaldehyde (20% EOB, 110 min). In both cases, the specific activity was found to be greater than 1 Ci/mumol (EOS). Animal studies in rats showed the percentage of the injected dose localizing in the whole brain to be 0.6 +/- 0.09 and 0.2 +/- 0.03 at 2 h post injection for the para- and the ortho-[18F]fluoro analogs of tropapride respectively. Cerebral biodistribution studies showed at 4 h a striatum uptake of 5 +/- 0.7% of the injected dose per gram of striatum for the para derivative with a low fixation into the frontal cortex and the cerebellum (% ID/g FC < 0.4 and % ID/g Cb < 0.3). The selectivity of 4-[18F]fluorotropapride for D2 dopaminergic sites was demonstrated through blocking experiments with ketanserin, spiperone and halopemide. The saturability was confirmed by the use of variable specific activities. These preliminary results showed that 4-[18F]fluorotropapride can be considered as a potent radiopharmaceutical for the study of the dopaminergic system with PET.
Centre de Recherches du Cyclotron - CRC
Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/5370

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Appl Radiat Isot 1992_Damhaut_18FTropapride.pdfNo commentaryPublisher postprint7.4 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.